Khaĭtov A
Vutr Boles. 1986;25(3):39-43.
The indications for cortisone administration as well as of its derivatives in the treatment of viral hepatitis (VH) have been discussed on the base of personal experience and literature data. It has been concluded that cortisone has lost its role in the treatment of VH because of its numerous negative effects, recurrences, steroid diabetes, ulcers, hemorrhages, liability to infections, and most important--the liability to chronification and long-term carriership in VHB. Manifested intoxication phenomena and impeding and present endogenic hepatic coma, remain for the present, the main indications for cortisone treatment in VH. In VHA and VH non A--non B it is not necessary and in VHB it could even by admitted to be contraindicated due to the risk of chronification and long-term carriership. It has been emphasized that post-transfusion hepatitis are with the severest course, responsible for the lethality, hence the main treatment in them remains the prophylaxis with passive and active immunization.
基于个人经验和文献数据，已对使用可的松及其衍生物治疗病毒性肝炎（VH）的适应症进行了讨论。得出的结论是，由于可的松有众多负面影响，如复发、类固醇性糖尿病、溃疡、出血、易感染，以及最重要的——易导致慢性化和乙型肝炎病毒（VHB）长期携带，因此它在治疗VH中已失去作用。目前，明显的中毒现象以及正在发生和即将发生的内源性肝昏迷，仍是VH中使用可的松治疗的主要适应症。在甲型肝炎（VHA）和非甲非乙型肝炎（VH非A–非B）中没有必要使用，而在VHB中，由于存在慢性化和长期携带的风险，甚至可认为是禁忌的。已强调指出，输血后肝炎病程最为严重，是致死的原因，因此其主要治疗方法仍是被动和主动免疫预防。
